PolyPid News

Analysts Conflicted on These Healthcare Names: Abbott Laboratories (ABT), PolyPid (PYPD) and GoodRx Holdings (GDRX)

TipRanksMay 20 17:50

PolyPid Enhances Share Option Plan to Motivate Staff

TipRanksMay 18 05:27

PolyPid Ltd. (NASDAQ:PYPD) Q1 2024 Earnings Call Transcript

Yahoo FinanceMay 11 05:25

Earnings Call Summary | PolyPid(PYPD.US) Q1 2024 Earnings Conference

The following is a summary of the PolyPid Ltd (PYPD) Q1 2024 Earnings Call Transcript:Financial Performance:PolyPid reported Q1 2024 cash and short-term deposits of $14.5 million.Research and developm

Futu NewsMay 10 22:57 · Conference Call

PolyPid Ltd (PYPD) Q1 2024 Earnings Call Transcript

PolyPid Ltd (PYPD) Q1 2024 Earnings Call Transcript

Earnings Call TranscriptsMay 10 10:38

PolyPid Reports Q1 Results

Seeking AlphaMay 9 04:51

Analysts Offer Insights on Healthcare Companies: PolyPid (PYPD) and Cartesian Therapeutics (RNAC)

TipRanksMay 8 23:32

Analysts Offer Insights on Healthcare Companies: PolyPid (PYPD) and Clene (CLNN)

TipRanksMay 8 23:20

PolyPid 1Q Loss $6.45M >PYPD

PolyPid 1Q Loss $6.45M >PYPD

Dow JonesMay 8 19:09

PolyPid 1Q Loss/Shr $1.37 >PYPD

PolyPid 1Q Loss/Shr $1.37 >PYPD

Dow JonesMay 8 19:09

PolyPid | 6-K: Report of foreign private issuer (related to financial reporting)

Futu NewsMay 8 19:08 · Announcements

PolyPid Q1 2024 GAAP EPS $(1.37) Beats $(1.58) Estimate

PolyPid (NASDAQ:PYPD) reported quarterly losses of $(1.37) per share which beat the analyst consensus estimate of $(1.58) by 13.29 percent. This is a 83.83 percent increase over losses of $(8.47) per

BenzingaMay 8 19:04

Press Release: PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results

PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results More Than 200 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX(100) for the Prevention of Abdominal Co

Dow JonesMay 8 19:00

PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results

Stockhouse May 8 19:00

PolyPid to Participate in Citizens JMP Life Sciences Conference

PETACH TIKVA, Israel, May 01, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced t

GlobeNewswireMay 1 19:00

HC Wainwright & Co. : The PolyPid (PYPD.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $14.00.

HC Wainwright & Co. : The PolyPid (PYPD.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $14.00.

Zhitong FinanceMay 1 18:30

HC Wainwright & Co. Reiterates Buy on PolyPid, Maintains $14 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates PolyPid with a Buy and maintains $14 price target.

Analyst UpgradesMay 1 18:27

PolyPid Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/01/2024 193.37% HC Wainwright & Co. → $14 Reiterates Buy → Buy 10/23/2023 109.55% Barclays $2.5 → $10 M

BenzingaMay 1 18:25

Buy Rating Affirmed for PolyPid on Strong Trial Progress and Expanding Pipeline Potential

TipRanksApr 30 21:06

PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections

Study Approximately Half Enrolled to the Planned Unblinded Interim Analysis Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up Top-line Results

GlobeNewswireApr 30 19:00